Balancing Local Water Needs with Global Supply Chains
Protecting our planet's most precious resource isn't just a matter of environmental stewardship. It's a substantial business problem.
Protecting our planet's most precious resource isn't just a matter of environmental stewardship. It's a substantial business problem.
As CSCOs shift into a second phase of their COVID-19 response, five key actions will help them prepare for recovery.
This five-pronged approach to reopening has proved to be effective, even as companies tailor their return to their specific culture and context.
By applying best practices during each phase of their response, manufacturers will be better positioned to survive the crisis and meet the surge in demand when the pandemic subsides.
COVID-19 and the New Leadership Agenda
The COVID-19 outbreak underscores the need to be resilient in the face of transformative global risk.
Manufacturers can implement win-win actions in their production and logistics operations that benefit the environment and create financial value.
Companies can reduce costly delays and add value by building agile into their factories.
To succeed in a future of electric vehicles, manufacturers must understand and prepare for the profound effects of this transformation on operations and labor requirements.
Companies may finally be able to achieve the long-awaited step change in the industry’s development—if they act collectively, rather than individually.
Shifting tariffs grab the headlines, but the rise of Southeast Asia and differences in worker productivity are also altering the cost equation for global manufacturing.
As a confluence of megatrends prompts companies to rethink their production and supply footprints, Southeast Asia is in position to become a greater force in international trade.
Where digital efforts have fallen short—and how to use human-machine collaboration to take performance to the next level.
As CSCOs shift into a second phase of their COVID-19 response, five key actions will help them prepare for recovery.
A big part of improving immunotherapy for patients may lie in digital technology and analytics.
